<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="269">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 07, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131453</url>
  </required_header>
  <id_info>
    <org_study_id>CCNP520A2202J</org_study_id>
    <secondary_id>2016-002976-28</secondary_id>
    <nct_id>NCT03131453</nct_id>
  </id_info>
  <brief_title>A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease</brief_title>
  <acronym>Generation S2</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banner Alzheimer's Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of CNP520 on cognition, global clinical
      status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for
      the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study uses a randomized, double-blind, placebo-controlled, parallel group, adaptive
      design with variable treatment duration in approximately 2000 cognitively unimpaired
      participants aged 60 to 75 years, with at least one APOE4 allele (Homozygotes or
      Heterozygotes) and, if Heterozygotes, with evidence of elevated brain amyloid.

      The screening period is expected to last about 12 weeks. Participants will receive disclosure
      of their individual test results for APOE genotyping and brain amyloid status.

      Treatment duration is variable (event driven trial) for at least 60 months, and up to an
      expected maximum of 84 months.

      Participants will return to the study site every three months for drug dispensing and every
      six months for safety and efficacy assessments, including neuropsychological scales with
      input from the study partner. Brain MRI scans will be conducted at month 6 and month 12, and
      on a yearly basis thereafter.

      The Follow-up visit will be scheduled 12 weeks after the end of the Treatment Epoch. An
      additional CSF and / or PET AD biomarker assessments will be conducted on a voluntary basis
      at year 2 and 5.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to event</measure>
    <time_frame>Through study completion, at least 5 years</time_frame>
    <description>Event is defined as diagnosis of MCI due to AD or dementia due to AD, whichever occurs first during the course of the study, after confirmation by the adjudication committee</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Composite score derived from the specific tests from the Repeatable Battery for the Assessment of Neurological Status (RBANS), Mini-Mental State Examination (MMSE), Raven's Progressive Matrices</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>To demonstrate the effects of CNP520, vs. placebo on global clinical status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>To demonstrate the effects of CNP520, vs. placebo on cognition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Everyday Cognition scale (ECog) total scores</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>To demonstrate the effects of CNP520, vs. placebo on function reported by the participant and study partner, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cerebral amyloid angiopathy (CAA)</measure>
    <time_frame>Through study completion, at least 5 years</time_frame>
    <description>To demonstrate the effects of CNP520 vs placebo on CAA, as measured by Magnetic Resonance Imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on volume of brain regions</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>To demonstrate the effects of CNP520 vs placebo on brain atrophy, as measured by volumetric Magnetic Resonance Imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amyloid deposition as measured by standardized uptake ratio (SUVR) of radiotracer positron emission tomography (PET) scan</measure>
    <time_frame>Baseline to Months 24 and 60</time_frame>
    <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF levels of Aβ40, Aβ42</measure>
    <time_frame>Baseline to Months 24 and 60</time_frame>
    <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF levels of total tau and phosphorylated tau</measure>
    <time_frame>Baseline to Months 24 and 60</time_frame>
    <description>To demonstrate the effects of CNP520 vs placebo on Alzheimer's Disease-related biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety</measure>
    <time_frame>Through study completion, at least 5 years</time_frame>
    <description>To demonstrate the safety and tolerability of CNP520 vs placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Arm#1: CNP520 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNP520 50 mg capsule given p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm#2: CNP520 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNP520 15 mg capsule given p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm#3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to CNP520 capsule given p.o.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNP520 50mg</intervention_name>
    <description>Arm#1</description>
    <arm_group_label>Arm#1: CNP520 50 mg</arm_group_label>
    <other_name>CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNP520 15mg</intervention_name>
    <description>Arm#2</description>
    <arm_group_label>Arm#2: CNP520 15 mg</arm_group_label>
    <other_name>CNP520 15 mg capsule p.o. for the duration of Treatment Epoch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to CNP520</intervention_name>
    <description>Arm#3</description>
    <arm_group_label>Arm#3: Placebo</arm_group_label>
    <other_name>Placebo to CNP520 p.o. for the duration of Treatment Epoch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  consent to receive disclosure of their risk estimates to develop clinical symptoms of
             AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
             amyloid.

          -  Male or female, age 60 to 75 years inclusive. Females must be considered
             post-menopausal and not of child bearing potential

          -  Cognitively unimpaired as evaluated by memory tests performed at screening.

          -  Participant's willingness to have a study partner.

          -  Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
             measured by CSF Abeta or amyloid PET imaging).

        Exclusion Criteria:

          -  Any disability that may prevent the participants from completing all study
             requirements. -

          -  Current medical or neurological condition that might impact cognition or performance
             on cognitive assessments.

          -  Advanced, severe progressive or unstable disease that may interfere with the safety,
             tolerability and study assessments, or put the participant at special risk.

          -  History of malignancy of any organ system, treated or untreated, within the past 60
             months.

          -  Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
             memantine).

          -  Contraindication or intolerance to MRI.

          -  Brain MRI results showing findings unrelated to AD that, in the opinion of the
             Investigator might be a leading cause to cognitive decline, might pose a risk to the
             participant, or might prevent a satisfactory MRI assessment for safety monitoring.

          -  Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.

          -  A positive drug screen at Screening, if, in the Investigator's opinion, this is due to
             drug abuse.

          -  Significantly abnormal laboratory results at Screening, not as a result of a temporary
             condition.

          -  Current clinically significant ECG findings.

          -  Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
             vitiligo) or active / history of chronic urticaria in the past year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>trialandresults.registries@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute, 901 East Willetta Street</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-839-6230</phone>
      <email>Kinal.bhatt@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Building B</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>623-832-6590</phone>
      <email>nadira.trncic@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research Inc, 3151 Airway Avenue T 3</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-277-4472</phone>
      <email>bshih@theatpgroup.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute, 25043 Narbonne Avenue</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-373-8120</phone>
      <email>jgarcia.010186@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-542-3008</phone>
      <phone_ext>310</phone_ext>
      <email>lorriebisesiphd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research LLC, 4925 Sheridan Street, Suite 200</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>706-455-1220</phone>
      <email>jriveros@infinityclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research, 2300 Maitland center, Pkwy Ste 230</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-644-1165</phone>
      <email>amarraffino@meridienresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Horizon Research Center, 11880 SW 40 St., Suite 405</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-226-3933</phone>
      <email>juliom@nhorizonresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience, 2230 Liliha st 104</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>808-261-4476</phone>
      <email>research@hawaiineuroscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic, 415 South 28th Avenue</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>601-579-5016</phone>
      <email>Kayleigh.Moring@hattiesburgclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Research Network, 2701 NW Vaughn St, Suite 350</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-293-5039</phone>
      <phone_ext>17</phone_ext>
      <email>afeldman@summitnetwork.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associate Ltd., 2325 Maryland Road, Suite 100</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-957-9250</phone>
      <email>denisegallagher.ana@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital and Memory Research Institute, 1018 Waterman Ave</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>401-435-8950</phone>
      <email>lgiven@rimmri.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <zip>53562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program, 1 Valleybrook Drive Suite 400</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>1 416 386 9761</phone>
      <email>sramotar@memorydisorders.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>October 5, 2017</lastchanged_date>
  <firstreceived_date>April 5, 2017</firstreceived_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Placebo controlled,</keyword>
  <keyword>APOE4 carriers,</keyword>
  <keyword>Homozygotes,</keyword>
  <keyword>Heterozygotes,</keyword>
  <keyword>Brain Amyloid,</keyword>
  <keyword>Preclinical Alzheimer's Disease (AD),</keyword>
  <keyword>Aβ lowering,</keyword>
  <keyword>BACE-1 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

